Dominant HCV genotype-3-specific T cell responses
| Dominant HCV genotype-3-specific T cell response | Number of Patients responding to epitope | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Viral region | AA position | Sequence | HLA | CD4/CD8 | Pept. set | S | C | A | Total |
| Core | 66–83 | PKARRSEGRSWAQPGYPW | ND | CD4 | OP | – | 5 | – | 5 |
| 143–158 | PVGGVARALAHGVRAL | ND | CD4 | OPs | – | 11 | 1TxN | 12 | |
| NS2 | 886–896 | LLYPSLIFDI | A02 | CD8 | HLA | – | 2 | 1AC | 3 |
| LYPSLIFDI | A24 | CD8 | – | 3 | 1AC | 4 | |||
| NS3 | 1443–1451 | ATDALMTGY | A01 | CD8 | HLA | – | 3 | 1TxS | 4 |
| 1520–1537 | RPSGMFDSVVLCECYDA DSVVLCECYDAGCSWYDL | ND | CD8 | OPs | 2 | 12 | – | 14 | |
| NS4b | 1853–1862 | RVLLDILAGY | A26 | CD8 | HLA | – | 3 | 1TxS 1SR | 5 |
| NS5a | 2126–2141 | AEFFTEVDGVRLHRYA | ND | CD8 | OPs | 2 | – | 2TxS | 4 |
Dominant T cell responses, defined as targeted in more than four patients within the Oxford HCV genotype-3 cohort, are depicted. For each targeted epitope, the amino acid (AA) position, peptide sequence, restricting HLA type, CD4/CD8 restriction and detecting peptide sets are specified. The total number of patients responding to the peptide and their status of infection (S, spontaneously resolved; C, chronic; A, acute; AC, acute proceeding to chronic; TxS, treated achieving SVR (sustained virological response); TxN, not responding to treatment; SR, spontaneously resolved) is detailed.
Underlining represents amino acids that are common between overlapping peptides. ND, not determined; OPs, overlapping peptides.